Dentsply Sirona (XRAY) Stock Rating Reaffirmed by Cleveland Research

Dentsply Sirona (NASDAQ:XRAY)‘s stock had its “hold” rating restated by equities research analysts at Cleveland Research in a research report issued to clients and investors on Thursday.

Other equities research analysts have also recently issued research reports about the company. JPMorgan Chase decreased their price target on Dentsply Sirona from $75.00 to $70.00 and set an “overweight” rating for the company in a research note on Monday, March 5th. Barrington Research reissued an “outperform” rating and issued a $70.00 price target (down previously from $73.00) on shares of Dentsply Sirona in a research note on Monday, March 5th. HC Wainwright set a $63.00 price target on Dentsply Sirona and gave the company a “hold” rating in a research note on Monday, March 5th. BidaskClub cut Dentsply Sirona from a “sell” rating to a “strong sell” rating in a research note on Wednesday, February 28th. Finally, Barclays began coverage on Dentsply Sirona in a research note on Thursday, March 8th. They issued an “equal weight” rating and a $62.00 price target for the company. Three research analysts have rated the stock with a sell rating, four have issued a hold rating and nine have given a buy rating to the company’s stock. The stock currently has an average rating of “Hold” and an average target price of $67.36.

How to Become a New Pot Stock Millionaire

Shares of XRAY stock opened at $49.02 on Thursday. The stock has a market capitalization of $11,488.92, a PE ratio of 18.43, a P/E/G ratio of 2.21 and a beta of 1.26. The company has a quick ratio of 1.45, a current ratio of 2.10 and a debt-to-equity ratio of 0.24. Dentsply Sirona has a 1-year low of $48.25 and a 1-year high of $68.98.

Dentsply Sirona (NASDAQ:XRAY) last issued its quarterly earnings results on Thursday, March 1st. The medical instruments supplier reported $0.82 earnings per share for the quarter, beating the consensus estimate of $0.81 by $0.01. The company had revenue of $1.09 billion during the quarter, compared to analysts’ expectations of $1.06 billion. Dentsply Sirona had a positive return on equity of 8.35% and a negative net margin of 39.39%. The business’s quarterly revenue was up 9.5% on a year-over-year basis. During the same quarter in the prior year, the firm posted $0.67 earnings per share. research analysts predict that Dentsply Sirona will post 2.74 earnings per share for the current year.

In related news, Director Eric Brandt sold 6,409 shares of the firm’s stock in a transaction that occurred on Monday, January 8th. The stock was sold at an average price of $68.04, for a total transaction of $436,068.36. Following the completion of the sale, the director now owns 12,073 shares of the company’s stock, valued at $821,446.92. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Company insiders own 1.99% of the company’s stock.

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. California Public Employees Retirement System grew its stake in Dentsply Sirona by 2.2% during the third quarter. California Public Employees Retirement System now owns 499,526 shares of the medical instruments supplier’s stock worth $29,877,000 after purchasing an additional 10,828 shares during the period. Victory Capital Management Inc. grew its stake in Dentsply Sirona by 22,502.5% during the fourth quarter. Victory Capital Management Inc. now owns 855,955 shares of the medical instruments supplier’s stock worth $56,348,000 after purchasing an additional 852,168 shares during the period. Wells Fargo & Company MN grew its stake in Dentsply Sirona by 3.1% in the third quarter. Wells Fargo & Company MN now owns 882,002 shares of the medical instruments supplier’s stock valued at $52,752,000 after acquiring an additional 26,125 shares during the period. Bank of Montreal Can grew its stake in Dentsply Sirona by 6.1% in the fourth quarter. Bank of Montreal Can now owns 211,583 shares of the medical instruments supplier’s stock valued at $13,929,000 after acquiring an additional 12,211 shares during the period. Finally, Alyeska Investment Group L.P. grew its stake in Dentsply Sirona by 223.7% in the third quarter. Alyeska Investment Group L.P. now owns 2,271,534 shares of the medical instruments supplier’s stock valued at $135,860,000 after acquiring an additional 1,569,746 shares during the period. 97.79% of the stock is owned by institutional investors and hedge funds.

TRADEMARK VIOLATION WARNING: This piece of content was posted by Ticker Report and is the property of of Ticker Report. If you are accessing this piece of content on another publication, it was stolen and republished in violation of US & international copyright & trademark legislation. The correct version of this piece of content can be viewed at https://www.tickerreport.com/banking-finance/3336986/dentsply-sirona-xray-stock-rating-reaffirmed-by-cleveland-research.html.

Dentsply Sirona Company Profile

DENTSPLY SIRONA Inc designs, develops, manufactures, and markets various dental and oral health products, and other consumable healthcare products primarily for the professional dental market worldwide. The company operates in two segments, Technologies & Equipment; and Consumables. Its dental supplies include endodontic instruments and materials, dental anesthetics, prophylaxis pastes, dental sealants, impression materials, restorative materials, tooth whiteners, and topical fluoride products; and small equipment products comprise dental hand pieces, intraoral curing light systems, dental diagnostic systems, and ultrasonic scalers and polishers.

Analyst Recommendations for Dentsply Sirona (NASDAQ:XRAY)

Receive News & Ratings for Dentsply Sirona Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dentsply Sirona and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Somewhat Favorable News Coverage Somewhat Unlikely to Affect Nuveen Energy MLP Total  Stock Price
Somewhat Favorable News Coverage Somewhat Unlikely to Affect Nuveen Energy MLP Total Stock Price
Brokerages Set Community Health Systems  Price Target at $5.79
Brokerages Set Community Health Systems Price Target at $5.79
Synovus  Expected to Post Earnings of $0.78 Per Share
Synovus Expected to Post Earnings of $0.78 Per Share
T2 Biosystems  Receives $5.94 Average PT from Brokerages
T2 Biosystems Receives $5.94 Average PT from Brokerages
Yescoin Price Up 5.1% This Week
Yescoin Price Up 5.1% This Week
RaiBlocks Trading Up 39.6% Over Last Week
RaiBlocks Trading Up 39.6% Over Last Week


© 2006-2018 Ticker Report. Google+.